Steven L Wagner, Phd
Steven L Wagner, Phd
Associate Professor of Neurosciences

University of California, San Diego)
USA

Education

Institution Date Degree/Field
Bellarmine College, Louisville, KY* 1980 B.A., Chemistry
University of Louisville, School of Medicine** 1984 M.S., Biochemistry
University of Louisville, School of Medicine 1985 Ph.D., Biochemistry
University of California, Irvine, College of Medicine*** 1989 NIH Postdoctoral Fellowship

 

Profile

Steven Wagner earned his MS and PhD degrees in biochemistry from the University of Louisville, School of Medicine and did post-doctoral training in microbiology and molecular genetics and UC Irvine College of Medicine.
He then served as Director of Biochemistry at the Salk institute Biotechnology/Industrial Associates, Inc., followed by a position as Chief Scientific Officer at Neurogenetics, Inc./TorreyPines Therapeutics, Inc. In 2009 he joined UC San Diego's Department of Neurosciences, where he currently is an associate professor and principal investigator.
Dr. Wagner's research focuses on the discovery, design and preclinical development of therapeutic small molecules known as gamma-secretase modulators (GSaMs). These drug-like small molecules are aimed at preventing and/or delaying the buildup of specific neuropathological lesions known as neuritic plaques that are invariably abundant in the brains of both patients with Down syndrome and Alzheimer's disease.

 

Research Interest

  • Dr. Wagner led the team that discovered the first non-NSAID-like and truly “Notch-sparing” gamma-secretase modulators and introduced the term “gamma-secretase modulators or GSMs” in 2005 (through the discovery of a novel series of diaryl-2-aminothiazole derivatives that are over 5000-fold more potent at lowering Aβ42 levels as are the NSAID-like “substrate-targeted” gamma-secretase modulators, e.g., sulindac sulphide and tarenflurbil).
    Since moving into the Department of Neurosciences at UCSD in 2009, his laboratory, in addition to designing/discovering another novel and structurally distinct, yet mechanistically-related 2-aminothiazole-containing GSM chemotype, has procured and validated all of the necessary immunochemical tools and differential screening assays (including high-throughput screening or HTS assays).
    In 2011 Dr. Wagner's team was awarded one of only seven Blueprint Neurotherapeutics (BPN) U01s by NIH/NINDS to optimize and develop more water soluble GSMs for Alzheimer’s disease (AD). These novel GSMs, termed soluble gamma-secretase modulators or SGSMs, have significantly improved physicochemical properties compared to the original GSM series.
    During the first three years of the project, his team has synthesized and identified a large number (>350) GSMs and also identified a subset of these which have excellent potency, brain penetration and oral bioavailability. They expect to begin IND enabling studies with their clinical candidate in 2014.

  • Professional Activities:

    NIH Postdoctoral Research Fellow Department of Microbiology and Molecular Genetics, College of Medicine, University of California, Irvine 1986 – 1989
    George E. Hewitt Foundation for Medical Research, Research Associate Department of Microbiology and Molecular Genetics, College of Medicine, University of California, Irvine 1989 – 1991
    Founder of Protease Corporation San Carlos, CA 1990 – 1991
    Director of Biochemistry The Salk Institute/Biotech. Indus. Assoc.,Inc. (SIBIA) 1991 – 1999
    Co-founder and Chief Scientific Officer TorreyPines Therapeutics, Inc 2000 - 2008
    Senior Research Specialist Department of Neurosciences, University of California San Diego 2009 - 2010
    Project Scientist, Principal Investigator Department of Neurosciences, University of California, San Diego 2010 – 2013
    Associate Professor in Residence Department of Neurosciences, University of California, San Diego 2013 – present

     

    Honors and Awards

     

     

    Publications

    1. Wagner SL, Dean WL and Gray RD. Effect of a zwitterionic detergent on the state of aggregation and catalytic activity of cytochrome P-450LM2 and NADPH-cytochrome P-450 reductase. 1984 J Biol Chem 259:2390-5
    2. Wagner SL and Gray RD. Effects of detergent on substrate binding and spin state of purified liver microsomal cytochrome P-450LM2 from phenobarbital-treated rabbits. 1985 Biochemistry 24:3809-14
    3. Wagner SL, Dean WL and Gray RD. Zwitterionic detergent mediated interaction of purified cytochrome P-450LM4 from 5,6-benzoflavone-treated rabbits with NADPH-cytochrome P-450 reductase. 1987 Biochemistry 26:2343-8
    4. Farrell DH, Wagner SL, Yuan RH and Cunningham DD. Localization of protease nexin-1 on the fibroblast extracellular matrix. 1988 J Cell Physiol 134:179-88
    5. Wagner SL, Van Nostrand WE, Lau AL and Cunningham DD. Monoclonal antibodies to protease nexin 1 that differentially block its inhibition of target proteases. 1988 Biochemistry 27:2173-6
    6. Van Nostrand WE, Wagner SL, and Cunningham DD. Purification of a form of protease nexin 1 that binds heparin with a low affinity. 1988 Biochemistry 27:2176-81
    7. Wagner SL, Lau AL and Cunningham DD. Binding of protease nexin-1 to the fibroblast surface alters its target proteinase specificity. 1989 J Biol Chem 264:611-5
    8. Wagner SL, Geddes JW, Cotman CW, Lau AL, Gurwitz D, Isackson PJ and Cunningham DD. Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease. 1989 Proc Natl Acad Sci U S A 86:8284-8
    9. Van Nostrand WE, Wagner SL, Suzuki M, Choi BH, Farrow JS, Geddes JW, Cotman CW and Cunningham DD. Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. 1989 Nature 341:546-9
    10. Van Nostrand WE, Wagner SL, Farrow JS and Cunningham DD. Immunopurification and protease inhibitory properties of protease nexin-2/amyloid beta-protein precursor. 1990 J Biol Chem 265:9591-4.
    11. Wagner SL, Lau AL, Nguyen A, Mimuro J, Loskutoff DJ, Isackson PJ and Cunningham DD. Inhibitors of urokinase and thrombin in cultured neural cells. 1991 J Neurochem 56:234-42
    12. Choi BH, Suzuki M, Kim T, Wagner SL and Cunningham DD. Protease nexin-1. Localization in the human brain suggests a protective role against extravasated serine proteases. 1990 Am J Pathol 1990 137:741-7
    13. Cunningham, D.D., Farrell, D.H., and Wagner, S.L. Regulation of Protease Nexin-1 Activity and Target Protease Specificity by the Extracellular Matrix.  In:  Serine Proteases  and Serpins in the Nervous System  1990 (B.W. Festoff, ed.)  NATO Scientific Affairs Division.
    14. Van Nostrand WE, Farrow JS, Wagner SL, Bhasin R, Goldgaber D, Cotman CW and Cunningham DD. The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2. 1991 Proc Natl Acad Sci U S A  88:10302-6
    15. Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmerman J, Cotman CW and Cunningham, DD.  Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. 1992 Proc Natl Acad Sci USA 89:2551-5
    16. Van Nostrand, W.E., Wagner, SL, Haan, J., Bakker, E., and Roos, R.A.C.  Decreased Cerebrospinal Fluid Levels of Amyloid Precursor Proteins in HCHWA:  A Common Feature in Cerebrovascular Amyloidoses.  1992 Ann. Neurol. 32:215-218.
    17. Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DD and Cotman CW. Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease. 1992 Neuroscience 48:763-77
    18. Kim, T.S., Choi, B.H., Van Nostrand, W.E., Wagner SL and Cunningham, D.D.  Expression of Protease Nexin-2/ABPP in Dorsal Root Ganglia in Man:  A Correlative Immunocytochemical and In Situ Hybridization Study.  1992 Mol. And Chem. Neuropath. 16:225-239.
    19. Van Nostrand WE, Schmaier AH and Wagner SL. Potential role of protease nexin-2/amyloid beta-protein precursor as a cerebral anticoagulant. 1992 Ann N Y Acad Sci 674:243-52
    20. Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, and Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease.  1992 Lancet 340:453-4
    21. Wagner SL, Siegel RS, Vedvick TS, Raschke WC and Van Nostrand WE. High level expression, purification, and characterization of the Kunitz-type protease inhibitor domain of protease nexin-2/amyloid beta-protein precursor. 1992 Biochem Biophys Res Commun 186:1138-45
    22. Wagner SL, Van Nostrand WE, Lau AL, Farrow JS, Suzuki M, Bartus RT, Schuppek R, Nguyen A, Cotman CW and Cunningham DD. Co-distribution of protease nexin-1 and protease nexin-2 in brains of non-human primates. 1993 Brain Res 626:90-8
    23. Schmaier AH, Dahl LD, Rozemuller AJ, Roos RA, Wagner SL, Chung R and Van Nostrand WE. Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa. 1993  J Clin Invest. 92:2090
    24. Farlow, M.R., Ghetti, B., Dlouhy, S., Giaccone, G., Bugiani, O., Tagliavini, F. and Wagner, SL Cerebrospinal Fluid Levels of Amyloid -Protein Precursor are Low in an Indiana Kindred with Gerstmann-Straussler-Scheinker disease.  1994 Neurology 44:1508-1510
    25. Wagner SL, Peskind ER, Nochlin D, Provow S, Farrow JS, Pandian MR, Cleveland M, Ito RK and Farlow MR. Decreased levels of soluble amyloid beta-protein precursor are associated with Alzheimer's disease in concordant and discordant monozygous twin pairs. 1994 Ann Neurol 36:215-20
    26. Van Nostrand WE, Schmaier AH, Neiditch BR, Siegel RS, Raschke WC, Sisodia SS and Wagner SL. Expression, purification, and characterization of the Kunitz-type proteinase inhibitor domain of the amyloid beta-protein precursor-like protein-2. 1994 Biochim Biophys Acta 1209:165-70
    27. Lo AC, Haass C, Wagner SL, Teplow DB and Sisodia SS. Metabolism of the "Swedish" amyloid precursor protein variant in Madin-Darby canine kidney cells. 1994 J Biol Chem 269:30966-73
    28. Wagner, SL, “Biological Functions of the Amyloid β-Protein Precursor,” In:  Aschall, F., Goate, A., The Pathobiology of Alzheimer’s Disease.  1995 Academic Press Inc., pp165-180.
    29. Van Nostrand WE, Schmaier AH, Siegel RS, Wagner SL and Raschke WC. Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz-type protease inhibitor domain of the amyloid beta-protein precursor. 1995 J Biol Chem 270 :22827-30
    30. Rowe, B.A., Siegel, R.S., Murphy, M.F., Vedvick, T.S., and Wagner, S.L.  Specific Patterns of Amyloid B-Protein Precursor Isoform Secretion and Proteolysis in Cultured Human Cells.  1995 Amyloid:  The International Journal of Experimental and Clinical Investigation 3: 100-109.
    31. Lannfelt L, Basun H, Wahlund LO, Rowe BA and Wagner SL. Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. 1995 Nat Med 1:829-32
    32. Munoz, B., Kounnas, M.Z., Srinivasan, K., Vernier, J.M., Wagner, SL and McDonald, I.A. Alzheimer’s Disease:  Drug Discovery Approaches Based on Attenuation of A Peptide Formation. 1997 ID Drug Alert 2:1-8
    33. Peskind ER, Leverenz J, Farlow MR, Ito RK, Provow SA, Siegel RS, Cleveland M, Morgan CH, Pandian MR, Corbin S, Nochlin D, Schellenberg GD, Raskind MA and Wagner SL. Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls. 1997 Alzheimer Dis Assoc Disord 11:201-6
    34. Almkvist O, Basun H, Wagner SL, Rowe BA, Wahlund LO and Lannfelt L. Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. 1997 Arch Neurol 54:641-4
    35. Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, Younkin SG, Holtz G, Wagner SL, Price DL, Sisodia SS and Gearhart JD. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. 1997 Hum Mol Genet 6:1535-41
    36. Anderson JJ, Holtz G, Baskin PP, Wang R, Mazzarelli L, Wagner SL and Menzaghi F. Reduced cerebrospinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits. 1999 Neuroscience 93:1409-20
    37. Lamb BT, Bardel KA, Kulnane LS, Anderson JJ, Holtz G, Wagner SL, Sisodia SS, and Hoeger EJ. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. 1999 Nat Neurosci 2:695-7.
    38. Wagner SL and Munoz B., Modulation of amyloid  protein precursor processing as a means of retarding progression of Alzheimer's disease.1999  J Clin Invest 104:1329-32
    39. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R and Koo EH. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway 2000 J Clin Invest 106: 1159-66
    40. Lesuisse C, Xu G, Anderson J, Wong PCY, Price DL, Tang F, Wagner SL and Borchelt DR  Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice 2001 Hum Mol Genet 10: 2525-2537
    41. Sanders AJ, Bertram L, Mullin K, Sampson AJ, Latifzai K, Basu S, Jones J, Kinney D, MacKenzie-Ignano L, Yu S, Albert MS, Moscarillo TJ, Go RCP, Bassett SS, Daly MJ, Laird NM, Wang G, Velicelebi G, Wagner SL, Becker KD, Tanzi RE and Blacker D  Genetic Association of Alzheimer’s Disease with Multiple Polymorphisms in Alpha-2-Macroglobulin 2003 Hum Mol Genet  12: 2765-76
    42. Jankowsky JL, Fadale DJ, Anderson J, Xu G, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG and Borchelt DR  Mutant presenilins specifically elevate the levels of the 42 residue -amyloid peptide in vivo:  evidence for augmentation of a 42-specific  secretase 2004 Hum Mol Genet  13: 159-170
    43. Tanzi RE, Moir RD and Wagner SL Clearance of Alzheimer’s Abeta peptide: the many roads to perdition 2004 Neuron 43: 605-608
    44. Song ES, Juliano MA, Juliano L, Fried MG, Wagner SL and Hersh LB  ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety 2004 J Biol Chem 279: 54216-20
    45. Roos J, Digregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, Zhang S, Safrina O, Kozak JA, Wagner SL, Cahalan MD, Velicelebi G and Stauderman KA  STIM 1, an essential and conserved component of store-operated calcium channel function 2005 J Cell Biol 169: 435-45
    46. Anderson J, Holtz G, Baskin P, Turner M, Rowe B, Wang B, Kounnas M and Wagner SL  Reductions in -amyloid concentrations in vivo by the secretase inhibitors BMS-289948 and BMS-299897 2005 Biochem Pharmacol 69: 689-698
    47. Bertram L, Parkinson M, Ingelsson M, Lange C, Ramasamy K, Mullin K, Menon R, Sampson AJ, Hsaio MY, Elliott KJ, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D and Tanzi RE  Family-based association between Alzheimer’s disease and variants in UBQLN1 2005 N Engl J Med  352: 884-894
    48. Hiltunen M, Lu A, Thomas AV, Romano DM, Kim M, Jones PB, Xie Z, Kounnas MZ, Wagner SL, Berezovska O, Hyman BT, Tesco G, Bertram L and Tanzi RE  Ubiquilin 1 modulates Amyloid precursor protein trafficking and Abeta secretion 2006 J Biol Chem 281: 32240-53
    49. Bertram L, Mullin K, Parkinson M, Hsaio M, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D and Tanzi RE  Is alpha-T catenin (VR22) an Alzheimer’s disease risk gene?  2007 J Med Genetics 44: e63
    50. Bertram L, Lange C, Mullin K, Parkinson M, Hsaio M, Hogan M, Schjeide BM, Hooli B, DiVitro J, Ionita J, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD and Tanzi RE   Genome-wide Association Reveals Putative Alzheimer’s Disease Susceptibility Loci in Addition to ApoE 2008 Hum Mol Genet 83: 1-10
    51. Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT and Herrup K  NSAIDs prevent, but not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease  2009 J Clin Invest 119: 3692-3702
    52. Kim M, Su J, Romano D, Truong MH, Mullin K, Hooli B, Norton D, Tesco G, Elliot K, Wagner SL, Moir RD, Becker KD and Tanzi RE  Potential late-onset Alzheimer’s disease mutations in the ADAM 10 gene attenuate {alpha}-secretase activity  2009 Hum Mol Genet 18: 3987-3896 (PMID 19608551)
    53. Salhei A, Faizi M, Coals D, Valetta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M and Mobley WC  Restoration of norepinephrine-modulated contextual memory in a mouse model of Down Syndrome  2009 Sci Transl Med 1: p7ra17 (DOI: 10.1126scitranslmed.3000258) PMID (20368182)
    54. Kounnas MZ, Danks AM, Cheng S, Tyree C, Mao L, Comer D, Yu C, Pleynet D, Nyugen P, Digregorio PJ, Page N, Ackerman E, Velicelebi G, Stauderman KA, Sisodia SS, Comer WT, Tanzi  RE and Wagner SL  Modulation of gamma secretase in vivo reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer’s disease 2010 Neuron 67:769-780
    55. Lessard, CB, Wagner, SL and Koo, EH  Presenilin and -Secretase:  And four equals one:  Presenilin takes the -secretase role by itself 2010 Proc. Natl. Acad. Sci. USA 107:21236-21237
    56. Vetrivel KS, Barman A, Chen Y, Nguyen PD, Wagner SL, Prabhakar R and Thinakaran G  Loss of cleavage at the ’-site contributes to apparent increase in -amyloid peptide (A) secretion by -secretase (BACE1)-glycophosphatidylinositol (GPI) processing of amyloid precursor protein 2011 J Biol Chem 286: 26166-26177
    57. Kounnas MZ, Ackermann E, Stauderman KA, Velicelebi G and Wagner SL Gamma-secretase Modulatory Compounds, Methods for Identifying Same and Uses Therefore 2011 PCT/WO2011/057214 A3
    58. Wagner SL, Cheng S, Mobley WC and Tanzi RE Compounds and Uses Thereof in Modulating Levels of Various Amyloid Beta Peptide Alloforms 2011 PCT/WO 2011/163636 A2
    59. Vetrivel KS, Barman A, Chen Y, Nguyen PD, Wagner SL, Prabhakar R and Thinakaran G  Loss of cleavage at b’-site contributes to apparent increase in b-amyloid peptide (Abeta) secretion by Beta-secretase (BACE1)-glycosylphosphatidylinositol (GPI) processing of amyloid precursor protein  2011 J. Biol. Chem. 286: 26166-26177 (PMID 21642424)
    60. Zeiger W, Vetrivel KS, Nguyen PD, Wagner SL, Villereal ML and Thinakaran G Ca2+ influx through store-operated calcium channels reduces Alzheimer’s disease Ab secretion  2011 J. Biol. Chem 288:26955-66. PMID (23902769)
    61. Vetrivel KS, Barman A, Chen Y, Nguyen PD, Wagner SL, Prabhakar R and Thinakaran G  Loss of cleavage at b’-site contributes to apparent increase in b-amyloid peptide (Abeta) secretion by Beta-secretase (BACE1)-glycosylphosphatidylinositol (GPI) processing of amyloid precursor protein  2011 J. Biol. Chem. 286: 26166-26177 (PMID 21642424)
    62. Wagner SL, Tanzi RE, Mobley WC and Galasko D Potential for Gamma-Secretase Modulators in the Treatment of Alzheimer’s Disease  2012 Arch Neurol 69: 1255-1258 PMID (22801784)
    63. Wagner SL, Cheng S, Mobley WC and Tanzi RE Novel Gamma-secretase Modulators with Improved Physicochemical and Pharmacological Properties 2013 DKT. 30423.35 USP1/SBA/HH
    64. Zeiger W, Vetrivel KS, Nguyen PD, Wagner SL, Villereal ML and Thinakaran G Ca2+ influx through store-operated calcium channels reduces Alzheimer’s disease Ab secretion  2013  J. Biol. Chem 288:26955-66. PMID (23902769)
    65. Wagner SL, Zhang C, Cheng S, Nguyen P, Zhang X, Rynearson KD,  Li Y, Sisodia SS, Mobley WC and Tanzi RE Soluble gamma-secretase modulators selectively inhibit the production of Ab42 and potently augment the production of numerous carboxy-truncated Ab species 2014 Biochemistry 53:702-13. doi: 10.1021/bi401537v. Epub 2014 Jan 2 PMID (24401146)
    66. Liu, Q., Waltz, S., Woodruff, G., Ouyang, J., Israel, M., Herrera, C., Sarsoza, F., Koo, E.H., Goldstein, L.S.B, Wagner, S.L. and Shauna H. Yuan  Human neurons from PS1 iPSC mutant carriers respond to a potent GSM and reveal different biomarkers 2014 JAMA Neurol 71: 1481-1489 doi:10.1001/jamaneurol. 2014.2482 (PMID 25285942)
    67. Wagner, S.L., Mobley, W.C. and Tanzi, R.E. Provisional Patent: SD2014-330-1 (application #62/073,553) 3-Aminopyridazine C Ring Derivatives as Potent Gamma-secrtease Modulators Filed Oct 31st, 2014
    68. Kim, YH, Choi, SH, Hebisch, M, Chen, J, D'Avanzo, C, Asselin, Hooli, B, Zhang, C, Muffat, J, Peitz, M Kovacs, DM, Wagner, SL, Tanzi, RE and Kim, DY APP and PSEN1 mutations induce β-amyloid and tau pathologies in a three-dimensional human neural cell culture system 2014 Nature 515: 274-278
    69. Zhang X, Hoey R, Dolios G, Nguyen P, Wagner SL, Li Y-M, Wang R, Koide S and Sisodia SS Single-chain variable fragment (ScFv) that targets nicastrin differentially affects processing of Notch and APP 2014  J Biol Chem. 289:34851-61. doi: 10.1074/jbc.M114.609636
    70. Weissmiller AM, Natera-Naranjo O, Reyna SM, Pearn ML, Zhao X,  Nguyen P, Cheng S, Goldstein LSB, Tanzi RE, Wagner SL, Mobley WC and Wu C.  A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: Evidence for a role for APP.  2015 PLOS One. DOI: 10.1371/journal.pone.0118379
    71. D’Avanzo, C., Sliwinski, C., Wagner, S.L., Tanzi, R.E., Kim, D.Y. and Kovacs, D.M.  γ-Secretase modulators reduce endogenous Aβ42 levels in human neural progenitor cells without altering neuronal differentiation.  2015 FASEB J. (in press)
    72. Das, U., Wang, L., Ganguly, A., Saikia, J.M., Wagner , S.L., Koo, E.H. and  Roy, S. Visualization of APP and BACE-1 approximation in neurons: new insights into the amyloidogenic pathway.  2015 Nat. Neurosci. (in press)
    73. Wagner, S.L., Mobley, W.C., Tanzi, R.E., Johnson, G., Buckle, R., Mayhew, N., Herr and R.J., Rynearson, K.D.  Potent Gamma-secretase Modulators.  2015 WO1 PCT/US15/58429

     

    neurology-flyer